Roche Holdings AG RHHBY on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes competition with Eli Lilly And Co. LLY and Novo Nordisk A/S NVO.The company announced it had advanced CT-388, its experimental obesity treatment, into a Phase 3 trial.The therapy entered Roche's pipeline through its 2023 acquisition of Carmot Therapeutics.RHHBY is demonstrating bullish strength. Follow the breaking ...

The pharmaceutical company said that giredestrant in combination with everolimus significantly improved progression-free survival in patients with advanced breast cancer. ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating investigational giredestrant in combination with everolimus in people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer previously treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor and endocrine therapy. The s. ...

evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in post-CDK inhibitor setting, compared with standard of care plus everolimus The all-oral combination was well tolerated and adverse events were consistent with the known safety profiles of the individual study treatments; no new safety signals were observed evERA is the first positive head-to-head phase III trial investigating an all-oral selective oestrogen receptor deg ...